More News

3 August 2021

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development

2 August 2021

Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

2 August 2021

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

31 July 2021

Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs

30 July 2021

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

29 July 2021

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

28 July 2021

PeptiDream and Takeda Expand Collaborative Research and License Agreement to Develop Peptide Drug Conjugates for CNS Diseases

28 July 2021

Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway

28 July 2021

Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

28 July 2021

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

28 July 2021

AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity

27 July 2021

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

22 July 2021

Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications

21 July 2021

NanoSyrinx raises £6.2m to develop its synthetic biology platform for targeted intracellular engineering

20 July 2021

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines

19 July 2021

Successful anti-cancer alliance extended

17 July 2021

GC LabCell and GC Cell to Merge, Creating a Premier Cell Therapy Company

16 July 2021

Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease

15 July 2021

PAQ Therapeutics Launches with $30 Million Series A to Develop Novel Therapies through Autophagy-Dependent Degradation

15 July 2021

Aragen Announces Partnership with Skyhawk Therapeutics, Aimed at Developing Novel Small Molecule Therapeutics that Correct RNA Expression

15 July 2021

Lilly Announces Acquisition of Protomer Technologies

13 July 2021

ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells

13 July 2021

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

13 July 2021

48Hour Discovery and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals

13 July 2021

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

13 July 2021

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

13 July 2021

Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

13 July 2021

Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme

9 July 2021

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

9 July 2021

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H4 Targeted Antibody Therapy Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CD73 Inhibitor Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

EpCAM-Targeted Antibodies Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective